Skip to main content
SpringerLink
Log in

Menstrual Disorders and Hyperandrogenism in Adolescence

  • Chapter
  • First Online:
Pediatric Endocrinology

Part of the book series: Contemporary Endocrinology ((COE))

  • 2674 Accesses

Abstract

The evaluation of menstrual disorders in adolescents requires special ­consideration. Adolescents are in the midst of developing physically and physiologically to achieve adult reproductive function. Thus, the normal variation in the age of onset of puberty and subsequent menarche should be taken into account when evaluating adolescent girls. Menarche will be delayed if puberty is delayed in onset.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rosenfield RL, Lipton RB, Drum ML. Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics. 2009;123(1):84–8.

    Article  PubMed  Google Scholar 

  2. Apter D, Viinikka L, Vihko R. Hormonal pattern of adolescent menstrual cycles. J Clin Endocrinol Metab. 1978;47(5):944–54.

    Article  PubMed  CAS  Google Scholar 

  3. Zhang K, Pollack S, Ghods A, Dicken C, Isaac B, Adel G, et al. Onset of ovulation after menarche in girls: a longitudinal study. J Clin Endocrinol Metab. 2008;93(4):1186–94.

    Article  PubMed  CAS  Google Scholar 

  4. American Academy of Pediatrics Committee on Adolescence, American College of Obstetricians and Gynecologists Committee on Adolescent Health Care, Diaz A, Laufer MR, Breech LL. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics. 2006;118(5):2245–50.

    Google Scholar 

  5. Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil. 1967;12(1 Pt 2):77–126.

    PubMed  CAS  Google Scholar 

  6. Rosenfield RL, Cooke DW, Radovick S. The ovary and female maturation. In: Sperling MA, editor. Pediatric endocrinology. 3rd ed. Philadelphia, PA: Elsevier; 2008. p. 530–609.

    Chapter  Google Scholar 

  7. Golan A, Langer R, Bukovsky I, Caspi E. Congenital anomalies of the mullerian system. Fertil Steril. 1989;51(5):747–55.

    PubMed  CAS  Google Scholar 

  8. Biason-Lauber A, De Filippo G, Konrad D, Scarano G, Nazzaro A, Schoenle EJ. WNT4 deficiency—a clinical phenotype distinct from the classic Mayer-Rokitansky-Kuster-Hauser syndrome: a case report. Hum Reprod. 2007;22(1):224–9.

    Article  PubMed  CAS  Google Scholar 

  9. March C. Acquired intrauterine adhesions. In: Adashi E, Rock J, Rosenwaks Z, editors. Reproductive endocrinology, surgery, and technology philadelphia. Philadelphia, PA: Lippincott-Raven; 1996. p. 1475–88.

    Google Scholar 

  10. Bondy CA. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007;92(1):10–25.

    Article  PubMed  CAS  Google Scholar 

  11. Goswami D, Conway GS. Premature ovarian failure. Hum Reprod Update. 2005;11(4):391–410.

    Article  PubMed  CAS  Google Scholar 

  12. Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009;360(6):606–14.

    Article  PubMed  CAS  Google Scholar 

  13. Layman LC, McDonough PG. Mutations of follicle stimulating hormone-beta and its receptor in human and mouse: genotype/phenotype. Mol Cell Endocrinol. 2000;161(1–2):9–17.

    Article  PubMed  CAS  Google Scholar 

  14. Namnoum AB, Merriam GR, Moses AM, Levine MA. Reproductive dysfunction in women with Albright’s hereditary osteodystrophy. J Clin Endocrinol Metab. 1998;83(3):824–9.

    Article  PubMed  CAS  Google Scholar 

  15. de Zegher F, Jaeken J. Endocrinology of the carbohydrate-deficient glycoprotein syndrome type 1 from birth through adolescence. Pediatr Res. 1995;37(4 Pt 1):395–401.

    Article  PubMed  Google Scholar 

  16. Layman LC. Genetics of human hypogonadotropic hypogonadism. Am J Med Genet. 1999;89(4):240–8.

    Article  PubMed  CAS  Google Scholar 

  17. Bose HS, Pescovitz OH, Miller WL. Spontaneous feminization in a 46,XX female patient with congenital lipoid adrenal hyperplasia due to a homozygous frameshift mutation in the steroidogenic acute regulatory protein. J Clin Endocrinol Metab. 1997;82(5):1511–5.

    Article  PubMed  CAS  Google Scholar 

  18. Root AW. Reversible isolated hypogonadotropic hypogonadism due to mutations in the neurokinin B regulation of gonadotropin-releasing hormone release. J Clin Endocrinol Metab. 2010;95(6):2625–9.

    Article  PubMed  CAS  Google Scholar 

  19. Pfaeffle RW, Savage JJ, Hunter CS, Palme C, Ahlmann M, Kumar P, et al. Four novel mutations of the LHX3 gene cause combined pituitary hormone deficiencies with or without limited neck rotation. J Clin Endocrinol Metab. 2007;92(5):1909–19.

    Article  PubMed  CAS  Google Scholar 

  20. Beranova M, Oliveira LMB, Bedecarrats GY, Schipani E, Vallejo M, Ammini AC, et al. Prevalence, phenotypic spectrum, and modes of inheritance of gonadotropin-releasing hormone receptor mutations in idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2001;86(4):1580–8.

    Article  PubMed  CAS  Google Scholar 

  21. Komatsu M, Kondo T, Yamauchi K, Yokokawa N, Ichikawa K, Ishihara M, et al. Antipituitary antibodies in patients with the primary empty sella ­syndrome. J Clin Endocrinol Metab. 1988;67(4): 633–8.

    Article  PubMed  CAS  Google Scholar 

  22. Hendricks SA, Lippe BM, Kaplan SA, Bentson JR. Hypothalamic atrophy with progressive hypopituitarism in an adolescent girl. J Clin Endocrinol Metab. 1981;52(3):562–4.

    Article  PubMed  CAS  Google Scholar 

  23. Rappaport R, Brauner R, Czernichow P, Thibaud E, Renier D, Zucker JM, et al. Effect of hypothalamic and pituitary irradiation on pubertal development in children with cranial tumors. J Clin Endocrinol Metab. 1982;54(6):1164–8.

    Article  PubMed  CAS  Google Scholar 

  24. Van den Berghe G, de Zegher F, Bouillon R. Clinical review 95: acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab. 1998;83(6):1827–34.

    Article  PubMed  Google Scholar 

  25. Becker AE, Grinspoon SK, Klibanski A, Herzog DB. Eating disorders. N Engl J Med. 1999;340(14): 1092–8.

    Article  PubMed  CAS  Google Scholar 

  26. Razdan AK, Rosenfield RL, Kim MH. Endocrinologic characteristics of partial ovarian failure. J Clin Endocrinol Metab. 1976;43(2):449–52.

    Article  PubMed  CAS  Google Scholar 

  27. Laughlin GA, Dominguez CE, Yen SSC. Nutritional and endocrine-metabolic aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab. 1998;83(1):25–32.

    Article  PubMed  CAS  Google Scholar 

  28. Edman CD, MacDonald PC. Effect of obesity on conversion of plasma androstenedione to estrone in ovulatory and anovulator young women. Am J Obstet Gynecol. 1978;130(4):456–61.

    PubMed  CAS  Google Scholar 

  29. Rosenfield RL, Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res. 2010;1364:186–97.

    Article  PubMed  CAS  Google Scholar 

  30. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA. 1992;267(9):1244–52.

    Article  PubMed  CAS  Google Scholar 

  31. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, Grossman AB, Besser GM, et al. Menstrual abnormalities in women with Cushing’s disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab. 1998;83(9):3083–8.

    Article  PubMed  CAS  Google Scholar 

  32. Winters SJ, Berga SL. Gonadal dysfunction in patients with thyroid disorders. Endocrinologist. 1997;7:167–73.

    Article  Google Scholar 

  33. Sauder SE, Frager M, Case GD, Kelch RP, Marshall JC. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine. J Clin Endocrinol Metab. 1984;59(5):941–8.

    Article  PubMed  CAS  Google Scholar 

  34. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet. 1998;352(9138):1455–61.

    Article  PubMed  CAS  Google Scholar 

  35. Klibanski A. Clinical practice, prolactinomas. N Engl J Med. 2010;362(13):1219–26.

    Article  PubMed  CAS  Google Scholar 

  36. Rosenfield RL. Current concepts of polycystic ovary syndrome. Baillieres Clin Obstet Gynaecol. 1997; 11(2):307–33.

    Article  PubMed  CAS  Google Scholar 

  37. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens J, Haseltine F, Merriam G, editors. Polycystic ovary syndrome. Cambridge, MA: Blackwell Scientific Publications; 1992. p. 377–84.

    Google Scholar 

  38. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–88.

    Article  PubMed  Google Scholar 

  39. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.

    Article  Google Scholar 

  40. Lowe P, Kovacs G, Howlett D. Incidence of polycystic ovaries and polycystic ovary syndrome amongst women in Melbourne, Australia. Aust N Z J Obstet Gynaecol. 2005;45(1):17–9.

    Article  PubMed  Google Scholar 

  41. Mortensen M, Ehrmann DA DA, Littlejohn E, Rosenfield RL. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab. 2009;94(5):1579–86.

    Article  PubMed  CAS  Google Scholar 

  42. Rosenfield RL. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92(3):787–96.

    Article  PubMed  CAS  Google Scholar 

  43. Ibanez L, Potau N, Zampolli M, Street ME, Carrascosa A. Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin-releasing hormone agonist testing. Fertil Steril. 1997;67(5):849–55.

    Article  PubMed  CAS  Google Scholar 

  44. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev. 1995;16(3):322–53.

    Article  PubMed  CAS  Google Scholar 

  45. Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999;28(2):265–93.

    Article  PubMed  CAS  Google Scholar 

  46. McCartney CR, Bellows AB, Gingrich MB, Hu Y, Evans WS, Marshall JC, et al. Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004;286(6):E902–8.

    Article  PubMed  CAS  Google Scholar 

  47. Hirshfeld-Cytron J, Barnes RB, Ehrmann DA, Caruso A, Mortensen MM, Rosenfield RL. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(5):1587–94.

    Article  PubMed  CAS  Google Scholar 

  48. Nelson VL, Legro RS, Strauss III JF, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999;13(6):946–57.

    Article  PubMed  CAS  Google Scholar 

  49. Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86(12):5925–33.

    Article  PubMed  CAS  Google Scholar 

  50. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223–36.

    Article  PubMed  CAS  Google Scholar 

  51. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(1):141–6.

    Article  PubMed  CAS  Google Scholar 

  52. Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab. 2006;91(4):1275–83.

    Article  PubMed  CAS  Google Scholar 

  53. Du X, Rosenfield RL, Qin K. KLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in women. J Clin Endocrinol Metab. 2009;94(7):2594–601.

    Article  PubMed  CAS  Google Scholar 

  54. Dewailly D, Pigny P, Soudan B, Catteau-Jonard S, Decanter C, Poncelet E, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Mullerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab. 2010;95(9):4399–405.

    Article  PubMed  CAS  Google Scholar 

  55. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary ­syndrome. Cochrane Database Syst Rev. 2003;(3): CD003053.

    Google Scholar 

  56. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82(2):524–30.

    Article  PubMed  CAS  Google Scholar 

  57. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82(7):2108–16.

    Article  PubMed  CAS  Google Scholar 

  58. Eid GM, Cottam DR, Velcu LM, Mattar SG, Korytkowski MT, Gosman G, et al. Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2005;1(2):77–80.

    Article  PubMed  Google Scholar 

  59. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millan JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2005;90(12):6364–9.

    Article  PubMed  CAS  Google Scholar 

  60. Foecking EM, Szabo M, Schwartz NB, Levine JE. Neuroendocrine consequences of prenatal androgen exposure in the female rat: absence of luteinizing hormone surges, suppression of progesterone receptor gene expression, and acceleration of the gonadotropin-releasing hormone pulse generator. Biol Reprod. 2005;72(6):1475–83.

    Article  PubMed  CAS  Google Scholar 

  61. Witchel SF, Lee PA, Suda-Hartman M, Hoffman EP. Hyperandrogenism and manifesting heterozygotes for 21-hydroxylase deficiency. Biochem Mol Med. 1997;62(2):151–8.

    Article  PubMed  CAS  Google Scholar 

  62. Hensleigh PA, Woodruff JD. Differential maternal-fetal response to androgenizing luteoma or hyperreactive luteinalis. Obstet Gynecol Surv. 1978;33:262–71.

    Article  PubMed  CAS  Google Scholar 

  63. Meldrum DR, Frumar AM, Shamonki IM, Benirschke K, Judd HL. Ovarian and adrenal steroidogenesis in a virilized patient with gonadotropin-resistant ovaries and hilus cell hyperplasia. Obstet Gynecol. 1980;56(2):216–21.

    PubMed  CAS  Google Scholar 

  64. Kaltsas GA, Mukherjee JJ, Jenkins PJ, Satta MA, Islam N, Monson JP, et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab. 1999;84(8):2731–5.

    Article  PubMed  CAS  Google Scholar 

  65. Speiser PW, Susin M, Sasano H, Bohrer S, Markowitz J. Ovarian hyperthecosis in the setting of portal hypertension. J Clin Endocrinol Metab. 2000;85(2):873–7.

    Article  PubMed  CAS  Google Scholar 

  66. Herzog AG. Menstrual disorders in women with epilepsy. Neurology. 2006;66(6 Suppl 3):S23–8.

    Article  PubMed  Google Scholar 

  67. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(4):1105–20.

    Article  PubMed  CAS  Google Scholar 

  68. Barnes RB, Rosenfield RL, Ehrmann DA, Cara JF, Cuttler L, Levitsky LL, et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 1994;79(5):1328–33.

    Article  PubMed  CAS  Google Scholar 

  69. Qin K, Rosenfield RL. Mutations of the hexose-6-phosphate dehydrogenase gene rarely cause hyperandrogenemic polycystic ovary syndrome. Steroids. 2010;76(1–2):135–9.

    PubMed  Google Scholar 

  70. Glickman SP, Rosenfield RL, Bergenstal RM, Helke J. Multiple androgenic abnormalities, including elevated free testosterone, in hyperprolactinemic women. J Clin Endocrinol Metab. 1982;55(2):251–7.

    Article  PubMed  CAS  Google Scholar 

  71. Kaltsas GA, Korbonits M, Isidori AM, Webb JA, Trainer PJ, Monson JP, et al. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing’s syndrome? Clin Endocrinol (Oxf). 2000;53(4):493–500.

    Article  CAS  Google Scholar 

  72. Futterweit W, Krieger DT. Pituitary tumors associated with hyperprolactinemia and polycystic ovarian disease. Fertil Steril. 1979;31(6):608–13.

    PubMed  CAS  Google Scholar 

  73. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science. 1974;185(4155):949–51.

    Article  PubMed  CAS  Google Scholar 

  74. National Centers for Health Statistics. National Health and Nutrition Examination Survey 2000 CDC Growth Charts: United States. 2000. Available at: http://www.cdc.gov/nchs/about/major/nhanes/growthcharts/datafiles.htm.

  75. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril. 1990;53(5):804–10.

    PubMed  CAS  Google Scholar 

  76. Ibanez L, Potau N, Zampolli M, Virdis R, Gussinye M, Carrascosa A, et al. Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: comparison with the gonadotropin-releasing hormone test. J Clin Endocrinol Metab. 1994;78(1):30–5.

    Article  PubMed  CAS  Google Scholar 

  77. Winslow KL, Toner JP, Brzyski RG, Oehninger SC, Acosta AA, Muasher SJ. The gonadotropin-releasing hormone agonist stimulation test—a sensitive predictor of performance in the flare-up in vitro fertilization cycle. Fertil Steril. 1991;56(4):711–7.

    PubMed  CAS  Google Scholar 

  78. Zimmer CA, Ehrmann DA, Rosenfield RL. Potential diagnostic utility of intermittent administration of short-acting gonadotropin-releasing hormone agonist in gonadotropin deficiency. Fertil Steril. 2010;94(7):2697–702.

    Article  PubMed  CAS  Google Scholar 

  79. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am. 2005;34(3):677–705.

    Article  PubMed  Google Scholar 

  80. Rosenfield RL. Polycystic ovary syndrome in adolescents. 2008. Available at: http://www.uptodate.com/index.

  81. Rosenfield RL. What every physician should know about polycystic ovary syndrome. Dermatol Ther. 2008;21(5):354–61.

    Article  PubMed  Google Scholar 

  82. Legro RS, Schlaff WD, Diamond MP, Coutifaris C, Casson PR, Brzyski RG, et al. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab. 2010;95(12):5305–13.

    Article  PubMed  CAS  Google Scholar 

  83. Escobar-Morreale HF, Sanchon R, San Millan JL. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women ­presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab. 2008;93(2):527–33.

    Article  PubMed  CAS  Google Scholar 

  84. Bidet M, Bellanne-Chantelot C, Galand-Portier M, Tardy V, Billaud L, Laborde K, et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab. 2009;94(5):1570–8.

    Article  PubMed  CAS  Google Scholar 

  85. Lutfallah C, Wang W, Mason JI, Chang YT, Haider A, Rich B, et al. Newly proposed hormonal criteria via genotypic proof for type II 3{beta}-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab. 2002;87(6):2611–22.

    Article  PubMed  CAS  Google Scholar 

  86. Valassi E, Klibanski A, Biller BMK. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010;95(3):1025–33.

    Article  PubMed  CAS  Google Scholar 

  87. Lock J, Le Grange D, Agras WS, Moye A, Bryson SW, Jo B. Randomized clinical trial comparing family-based treatment with adolescent-focused individual therapy for adolescents with anorexia nervosa. Arch Gen Psychiatry. 2010;67(10):1025–32.

    Article  PubMed  Google Scholar 

  88. Miller KK, Lee EE, Lawson EA, Misra M, Minihan J, Grinspoon SK, et al. Determinants of skeletal loss and recovery in anorexia nervosa. J Clin Endocrinol Metab. 2006;91(8):2931–7.

    Article  PubMed  CAS  Google Scholar 

  89. Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang Jr T, Root AW. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab. 2005;90(12):6424–30.

    Article  PubMed  CAS  Google Scholar 

  90. Chernausek SD, Attie KM, Cara JF, Rosenfeld RG, Frane J. Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. Genentech, Inc., Collaborative Study Group. J Clin Endocrinol Metab. 2000;85(7):2439–45.

    Article  PubMed  CAS  Google Scholar 

  91. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol. 1994;170(5 Pt 1):1213–23.

    PubMed  CAS  Google Scholar 

  92. Farmer RD, Lawrenson RA, Todd JC, Williams TJ, MacRae KD, Tyrer F, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol. 2000;49(6):580–90.

    Article  PubMed  CAS  Google Scholar 

  93. Renoux C, Dell’aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case–control study. BMJ. 2010;340:c2519.

    Article  PubMed  Google Scholar 

  94. Rosenfield RL, Bickel S, Razdan AK. Amenorrhea related to progestin excess in congenital adrenal hyperplasia. Obstet Gynecol. 1980;56(2):208–15.

    PubMed  CAS  Google Scholar 

  95. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95(5):2038–49.

    Article  PubMed  CAS  Google Scholar 

  96. Swiglo BA, Cosma M, Flynn DN, Kurtz DM, Labella ML, Mullan RJ, et al. Clinical review: antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab. 2008;93(4):1153–60.

    Article  PubMed  Google Scholar 

  97. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 2009;92(6):1966–82.

    Article  PubMed  Google Scholar 

  98. Ibanez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab. 2000;85(9):3251–5.

    Article  PubMed  CAS  Google Scholar 

  99. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab. 2002;87(2):569–74.

    Article  PubMed  CAS  Google Scholar 

  100. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85(1):139–46.

    Article  PubMed  CAS  Google Scholar 

  101. Eisenhardt S, Schwarzmann N, Henschel V, Germeyer A, von Wolff M, Hamann A, et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2006;91(3):946–52.

    Article  PubMed  CAS  Google Scholar 

  102. Salley KES, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. POSITION STATEMENT: Glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007;92(12): 4546–56.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, CMSC 406, Baltimore, MD, 21287, USA

    Sara A. DiVall M.D.

  2. Departments of Medicine and Pediatrics, Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, The University of Chicago Medical Center, Chicago, IL, USA

    Robert L. Rosenfield M.D.

Authors
  1. Sara A. DiVall M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert L. Rosenfield M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sara A. DiVall M.D. .

Editor information

Editors and Affiliations

  1. School of Medicine, Department of Pediatrics, The Johns Hopkins University, 600 North Wolfe St., Baltimore, 21287, Maryland, USA

    Sally Radovick

  2. , Department of Pediatrics, Children's Hospital of Buffalo, 219 Bryant St., Buffalo, 14222, New York, USA

    Margaret H. MacGillivray

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

DiVall, S.A., Rosenfield, R.L. (2013). Menstrual Disorders and Hyperandrogenism in Adolescence. In: Radovick, S., MacGillivray, M. (eds) Pediatric Endocrinology. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-395-4_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-395-4_25

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-394-7

  • Online ISBN: 978-1-60761-395-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation